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Kell and Kx blood group systems
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The Kell and Kx blood group systems are expressed as covalently 
linked molecules on red blood cells (RBCs). The Kell blood 
group system is very polymorphic, with 35 antigens assigned to 
the system. The expression of Kell glycoprotein on RBCs is not 
critical to the erythrocyte function. However, the expression 
of Kx is critical to normal morphology, and null mutations are 
associated with the McLeod neuroacanthocytosis syndrome. The 
immunogenicity of the K antigen is second only to the D antigen, 
and alloantibodies to Kell antigens can cause transfusion 
reactions and hemolytic disease of the fetus and newborn. 
Kell alloantibodies in pregnancy are known to suppress 
erythropoiesis, which can result in serious disease despite low 
amniotic bilirubin levels and low antibody titers. Late-onset 
anemia with reticulocytopenia is thought to be attributable 
to the continual suppression of erythropoiesis from residual 
alloantibody in the infant. Alloimmunization to XK protein is rare, 
and expressed polymorphisms have not been reported. Together 
these two blood group systems share an integral relationship in 
transfusion medicine, neurology, and musculoskeletal biology. 
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Kell glycoprotein is a single-pass type II transmembrane 
moiety expressed on red blood cells (RBCs).1 Kell is highly 
polymorphic, expressing 7 sets of 15 antithetical antigens (one 
set is triallelic), 2 low prevalent antigens, and 18 high prevalent 
antigens.2 The first alloantibody was discovered in 1946 as the 
result of hemolytic disease of the fetus and newborn (HDFN). 
The name of the antigen, “Kell”, was taken from the last name 
of the woman whose serum contained the antibody.3 The 
maternal antibody reacted with paternal and infant RBCs and 
reacted retrospectively with RBCs from their firstborn child. 
An incidence of 9 percent among random blood donors was 
indicative of a new blood group antigen. A few years later, 
the antithetical antigen was identified.4 Together, they were 
known as Kell/Cellano antigens, which are now named K/k 
or KEL1/KEL2. To this day, reference to the K antigen often is 
confused by the inappropriate use of the term “Kell” because it 
is also the name of the blood group system.
The Kell and Kx blood group systems are discussed together 
because their antigens are expressed on the surface of RBCs 
as covalent-linked moieties (Fig. 1). An eloquent historical 
perspective of the landmark discoveries and relationships 
between Kell glycoprotein and XK protein was reviewed in 
Redman and Lee.6 Suffice it to say that the discovery of these 
two blood group systems relied on RBC serological, biochemical, 
immunohistochemistry, and molecular observations. The fact 
that Kell glycoprotein is particularly immunogenic in humans 
revie w
Fig. 1. Schematic diagram of the Kell–XK protein complex. Kell 
glycoprotein is a single-pass transmembrane spanning (single 
cylinder) type II moiety, with its N-terminal on the cytoplasmic side 
(designated as In). XK protein is a multipass transmembrane spanning 
(horizontal stacked cylinders) moiety. The two polypeptides are linked 
by a single disulfide bond (Kell amino acid 72 to XK amino acid 347). 
Note the numerous cysteine residues on the Kell glycoprotein and 
thus the susceptibility of antigens to 2-aminoethyl-isothiouronium 
bromide and dithiothreitol AET (2-aminoethylisothiouronium 
bromide) treatment. HELLH represents the histidine-glutamate-
leucine-leucine-histidine metalloendopeptidase activity motif. 
Reprinted from Seminars in Hematology, vol. 37, p. 117, copyright 
2000,5 used with permission.
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provided multiple sources of the alloantibodies and antigen-
negative RBCs.
It is important to note that although Kell and XK are 
covalently linked molecules on RBCs, they are not necessarily 
expressed together in other tissues. Kell is expressed in 
testis, brain, and muscle. XK is found in muscle, heart, and 
brain. Expressed sequence tagged analyses show that KEL is 
expressed in cDNA libraries from bone marrow, macrophages, 
spleen, and brain. XK was detected in cDNA from the same 
libraries and was detected in peripheral nervous tissue, and 
eye. Interestingly, KEL, but not XK, is detected in 8- and 
9-week-old embryo libraries.7–9
Kell glycoprotein shares sequence homology with M13 
family neutral zinc-dependent endopeptidases, and has 
been demonstrated to have endothelin-converting enzyme-1 
activity. RBCs expressing Kell glycoprotein can cleave big 
endothelin 3 into its bioactive peptide. The expression of 
Kell glycoprotein on RBCs does not appear to be critical to 
red cell membrane structure or function, however.10 The Kell 
glycoprotein forms part of a surface membrane complex with 
glycophorin C and D because it has been demonstrated that 
Kell antigens are weakly expressed with the Ge:-3 phenotype 
or when glycophorin C/D are absent (Leach phenotype).11
The Kx blood group system is a multi-pass transmembrane 
moiety and contains one antigen, the XK protein. It is predicted 
to traverse the plasma membrane 10 times and, because of 
this structure, is thought to be a membrane transporter.12 
This protein is biologically important because the absence 
of XK protein results in RBC morphological changes called 
acanthocytosis and leads to the midlife onset of neuromuscular 
abnormalities known as the McLeod neuroacanthocytosis 
syndrome.13
Kell and XK Proteins
Kell glycoprotein has 732 amino acids and contains 
five N-glycosylation sites, with the threonine to methionine 
substitution at position 193 resulting in a loss of one 
N-glycosylation site. Therefore, Kell glycoprotein expressing 
a methionine at position 193 (K antigen) migrates faster in 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
than the version with threonine at that position. Kell 
glycoprotein has 15 cysteine residues on the exofacial domain. 
The Cys72 forms a disulfide bond with Cys347 of the XK 
protein. It is because of several internal cysteine–cysteine 
bonds that Kell antigens are sensitive to disulfide bond 
reducing agents (2-aminoethyl-isothiouronium bromide 
and dithiothreitol). The metalloendopeptidase activity is 
attributable to a conserved HxxLH motif (histidine-glutamate-
leucine-leucine-histidine in Kell glycoprotein) at amino acid 
positions 581–585. The three-dimensional structure of 
Kell glycoprotein has been modeled on the crystal structure 
of neutral endopeptidase 24.11. Lee and coworkers noted 
that most of the Kell antigens are the result of amino acid 
changes in the non-conserved exofacial globular domain.14 
The expression of Kell glycoprotein is weaker than normally 
observed when it contains a glutamate at position 281 (i.e., 
Kpa antigen). In other words, a reduced amount of K antigen 
can be shown when RBCs are Kp(a+)15,16 although K antigen 
expression is unaffected. The reason for this observation is that 
K antigen contains an arginine at position 281, i.e., Kp(b+). It 
was noted that K and Kpa would not be observed in cis moiety 
because both are low prevalence antigens. The probability 
is exceedingly rare for a non-sister chromatic exchange or 
sequential mutation at both nucleotide positions to create this 
haplotype. But the Kpa-associated reduced expression was 
confirmed with the characterization of a KEL*1,3 allele.17 Kell 
glycoprotein has been reported to be weakly expressed in the 
presence of autoantibodies showing Kell specificity. However, 
it is important to evaluate the phenomenon carefully because 
of the immunoglobulin M (IgM) autoantibody masking of Kell 
antigens, as shown by Zimring and colleagues. Their eloquent 
study also showed that antibodies to Kpb sterically hinder the 
binding of anti-K to its cognate epitope.18,19
The XK protein comprises 444 amino acids and has no 
known polymorphisms leading another blood group antigen. 
The moiety is not glycosylated.12 RBCs are deemed to have the 
McLeod phenotype when they lack Kx antigens and weakly 
express Kell antigens and when mild hemolysis is observed 
in the patient with or without acanthocytosis. The McLeod 
phenotype may be part of the McLeod neuroacanthocytosis 
syndrome in which neurological and musculoskeletal 
abnormalities are also present.13,20
Kell and XK Genes
The gene responsible for the expression of Kell 
glycoprotein was cloned in 1991. Lee and coworkers used a 
short oligonucleotide probe deduced from a tryptic peptide of 
the proposed glycoprotein to screen a λgt cDNA library. Later 
in 1995, Lee reported that KEL was organized into 19 exons 
and spanned approximately 21.5 kilobasepair. Genetic linkage 
analysis with prolactin-inducible protein by Zelinski et al. 
mapped KEL to chromosome 7q32-36. Lee showed that KEL 
maps to 7q33.1,21,22
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The distinguishing feature of KEL is that it is predicted 
to be a type II single transmembrane spanning protein; the 
N-terminal is on the cytoplasmic side of the plasma membrane. 
The metalloendopeptide studies were performed on the basis 
of sequence homology with neutral endopeptides and the fact 
that the positions of many of the cysteines are conserved.10,23 
Lee determined the molecular basis of KEL1/KEL2 and, with 
that publication, the ability to predict fetal inheritance of KEL1 
and hemolytic disease using amniotic fluid–derived DNA. The 
molecular basis for Jsa/Jsb was reported in that same year. 
The molecular basis for Kpa, Kpb, and Kpc followed in 1996.24–26 
Table 1 summarizes the molecular features for the Kell blood 
group system antigens.
The lack of Kell expression has lead to a number of 
nucleotide changes responsible for the Kell-null phenotype. 
The nucleotide changes result in alternative splice sites, 
amino acid substitutions deleterious to expression, nucleotide 
insertions and deletions causing frameshifts, and termination 
codons.27,28 In addition, several nucleotide changes result in 
the reduced expression of Kell glycoprotein, termed Kmod 
phenotype. The amino acid change for KEL13 not only causes 
the loss of the high prevalence antigen but also reduces the 
expression of Kell glycoprotein.29
Kell and Kx Antigens
The principle antigens K/k, Kpa/Kpb, and Jsa/Jsb are 
invariably included in commercially available reagent RBC 
panels (Table 1). The K antigen is considered the most 
immunogenic among the minor blood group antigens, with 
the exception of the D antigen, which is nearly always matched 
in RBC transfusions. In fact, the K antigen has been given an 
immunogenicity index of 1.0 by Tormey and Stack, and is the 
antigen with which all other minor blood group antigens are 
compared for the purpose of ranking immunogenicity (save for 
the D antigen).30,31 The frequency of anti-K in pregnancy also 
attests to its immunogenicity, although a significant proportion 
of anti-K in pregnancy is the result of the transfusion of 
K+ RBCs to K– women prior to pregnancy, since K antigen 
matching is not mandatory. Approximately 15–20 percent 
of RBC alloimmunizations seen in pregnancy are caused by 
anti-K.32 The immunogenicity of K antigen may be HLA-
related. The frequency of HLA-DRB1*11 and HLA-DRB1*13 
are statistically higher in anti-K alloimmunized patients 
versus matched controls. This observation led Chiaroni et 
al. to conclude that the immune response to K is partially 
attributable to preferred association of HLA type for antigen 
presentation.33
The prevalence of Jsa and Jsb antigens in people of African 
ancestry (20% and 80%, respectively) is unique to this racial 
population. The prevalence of Js(a+b–) is approximately 1 
percent, and therefore anti-Jsb alloimmunization is observed 
Table 1. Molecular features, nucleotide polymorphisms, and 
antigens of the Kell blood group system
System: Kell, CD328
Location: 7q33
Gene Name: KEL, ISBT 006
Gene Size: 21,302 basepair
mRNA Size: 2,562 basepair
Nucleotide Exon rs# Antigen(s) Amino acid
578C>T 6 8176058 KEL2/KEL1 (K/k) Thr193Met
577T>A 6 61729031 KEL1w+ (Kmod) Thr193Ser
841C>T 8 876059 KEL4/KEL3 [Kpa/Kpb)] Arg281Trp
842G>A 8 — KEL21 [Kp(a-b-c+)] Arg281Gln
1790T>C 17 8176038 KEL7/KEL6 [Jsa/Jsb)] Leu597Pro
905T>C 8 — KEL11/KEL17 Val302Ala
539G>C 6 61729039 KEL14/KEL24 Arg180Pro
539G>A 6 — KEL14 (KEL:-14) Arg180His
538C>T 6 — KEL14/KEL24  
(KEL:-14,-24)
Arg180Cys
742C>T 8 61728832 KEL25/KEL28  
(VLAN-/VONG+)
Arg248Gln
743G>A 8 61729040 KEL25/KEL28  
(VLAN+/VONG-)
Arg248Trp
875G>A 8 201698610 KEL31/KEL38  
(KYOR+/KYOR-)
Arg292Gln
1481A>T 13 — KEL10 (Ula) Glu494Val
1643A>G 15 — KEL12 His548ARg
986T>C 9 — KEL13 (Kmod) Leu329Pro
388C>T 4 184131044 KEL18 Arg130Trp
389G>A 4 201110152 KEL18 Arg130Gln
1475G>A 13 — KEL19 Arg492Gln
965C>T 9 — KEL22 Ala322Val
1145A>G 10 — KEL23 Gln382Arg
1217G>A 11 — KEL26 (TOU) Arg406Gln
745G>A 8 61729042 KEL27 (RAZ) Glu249Lys
1868G>A 17 — KEL29 (KALT) ARg623Lys
913G>A 8 — KEL30 (KTIM) Asp305Asn
1271C>T 11 — KEL32 (KUCI) Ala424Val
1283G>T 11 — KEL33 (KANT) Arg428Leu
758A>G 8 — KEL34 (KASH) Tyr253Cys
780G>T 8
18
— KEL35 (KELP) Leu260Phe
Arg675Gln
1391T>C 12 190890637 KEL36 (KETI) Thr464Ile
877C>T 8 — KEL37 (KHUL) Arg293Trp
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occasionally in transfusion recipients, including chronically 
transfused patients with sickle cell disease. These patients 
pose particular challenges when requiring Js(b–) blood. 
Transfusing institutions and blood centers must rely on 
continued surveillance of suitable donors and on the American 
Rare Donor Program. On the other hand, the prevalence of K 
antigen does not create challenges when providing compatible 
blood.
Nearly all Kell blood group system antigens are caused by 
single nucleotide polymorphisms leading to single amino acid 
substitutions. The K:-35 phenotype is the result of two amino 
acid substitutions at positions 260 and 675.
Kell and Kx Antibodies
Kell blood group system antibodies are usually IgG, but 
can also be IgM. As a result, anti-K has been manufactured as 
IgM monoclonal antibodies with sufficient avidity to be used 
as phenotyping reagents. The antibodies can cause acute and 
delayed hemolytic transfusion reactions, and autoantibodies 
with Kell specificities have been reported. As stated previously, 
alloantibodies to this blood group system cause HDFN. It is 
likely that all Kell blood group system antibodies suppress 
erythropoiesis. Antibodies to the XK protein would react 
similarly using in vitro techniques. Antibodies to the XK 
protein are not found naturally occurring.
Many single nucleotide polymorphisms lead to the K0 
(i.e., the complete absence of Kell glycoprotein) phenotype, 
and with that phenotype the possibility of alloimmunization 
is high. The antibody produced by K0 transfusion recipients 
is anti-Ku (K5). The serum of alloimmunized K0 persons 
represents antibodies to the Kell glycoprotein in much the 
same way as polyclonal anti-D or anti-U; it contains antibodies 
to multiple epitopes expressed on the Kell glycoprotein. Anti-
Ku is exceedingly rare—there are only ~100 K0 phenotypes 
described worldwide. Persons with marked reduction in the 
expression of Kell antigens, i.e., the Kmod phenotype, are 
at risk of forming antibodies to the epitope(s) expressed on 
wild-type Kell that they lack. Kmod variant is not mutually 
compatible, although the risk of alloimmunization of Kmod 
RBC transfusions to a Kmod recipient is lower because of the 
lower dose of antigen. Theoretically, K0 transfusion recipients 
are not tolerant of Kmod transfusions, but the immunogenicity 
of Kmod RBCs is unknown.
When the XK protein is absent (McLeod phenotype), 
transfusion recipients are at risk of forming anti-Kx along 
with anti-Km (K20). It is generally reported that major 
chromosomal deletions that include XK and the gene 
responsible for chronic granulomatous disease (CGD) make 
anti-Kx+Km.34 The McLeod phenotype without CGD results 
in anti-Km alloimmunization. Exceptions, however, have been 
reported of anti-Kx without anti-Km in XK−CGD deletions, 
and anti-Kx+Km in McLeod neuroacanthocytosis syndrome 
without CGD.35,36
Hemolytic Disease of the Fetus and Newborn
HDFN attributable to Kell blood group system antibodies 
has unique clinical features. The antibody titers do not 
correlate with disease severity nor are amniotic fluid bilirubin 
levels consistent with disease severity.37 The disease appears 
much more severe than titers indicate. A critical titer of 8 for 
intervention is recommended—however, middle cardiac vein 
Doppler echocardiography has changed the management of 
HDFN.38,39 Kell glycoprotein is known to be expressed early 
in fetal erythropoiesis.40 Therefore, it is assumed that HDFN 
can occur earlier in gestation, when RBCs begin to form. For 
example, maternal anti-K in the fetal circulation can bind to the 
fetal K antigen expressed on early erythroid progenitor cells, 
which are thus removed by the fetal mononuclear phagocytic 
system. In vitro studies by Daniels and coworkers showed that 
peripheral blood mononuclear cells from cord blood (a source 
of CD34+ and early hematopoietic progenitor cells) grown in 
the presence of erythropoietin bound anti-K, but not anti-D, 
after 7 days of culture. Further, they showed that these cells 
had a high opsonization index (i.e., the antibody sensitized 
red cells are susceptible to phagocytosis). The observation 
suggests that, in part, profound anemia may be caused by 
the early destruction of erythroid progenitor cells in the fetus 
before a significant amount of hemoglobin could accumulate 
in the cells.41 Thus, early erythroid RBC destruction does not 
correlate with the degree of anemia or amniotic fluid bilirubin 
levels.
Vaughan and coworkers cultured cord blood mononuclear 
cells (a source of hematopoietic progenitor cells) with 
erythropoietin in a semi-solid agar to enumerate erythroid 
colony-forming and burst-forming units. They showed 
that anti-K suppressed erythropoiesis in an antibody dose-
dependent manner. Therefore, both phagocytosis of early 
erythroid progenitor cells and suppressed erythropoiesis 
contribute to disease severity that does not correlate with 
titers or evidence of RBC destruction.42 The suppressive 
effect of anti-K goes beyond gestation. Residual alloantibody 
in the newborn can continue to ongoing suppression of 
erythropoiesis. Suppressed erythropoiesis is supported 
by the lack of reticulocytosis that is normally observed in 
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newborns.37,43 Infants who are supported by allogeneic top-
up or exchange transfusions may appear well a few days after 
delivery, but are at risk of late-onset anemia as the antibodies 
continue to cause RBC destruction (as they would with anti-D) 
along with suppression of erythropoiesis. The result is a risk of 
late-onset anemia within a couple of weeks as the transfused 
RBCs are sequestered and the infant’s marrow is unable to 
produce sufficient RBCs.
Conclusions
Antibodies to the Kell and Kx blood group systems 
provide serological challenges in immunohematology. The 
K antigen is among the most immunogenic antigen, and 
the expression of a covalent-linked complex with the XK 
protein and the non-covalent interactions with glycophorin 
C underscore the importance of Kell and XK in membrane 
integrity and cellular function. The transfusion of K+ RBCs to 
women of childbearing potential remains controversial given 
the significant incidence of anti-K HDFN. Kell blood group 
antibodies do more than bind to their cognate antigen, which 
makes the Kell-XK blood group systems clinically relevant and 
scientifically challenging. The antibody-mediated intracellular 
signaling events responsible for suppressed erythropoiesis 
remain to be characterized. The prevention of anti-K HDFN 
by passive immunization in a similar way as anti-D is unlikely 
practical. Identification of immunodominant epitopes and a 
better understanding of T-cell tolerance induction may lead to 
a new era of immunotherapy for the prevention of HDFN.44
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